Breaking News, Collaborations & Alliances

Evergreen Theragnostics to Manufacture MTTI’s EvaThera Radiopharmaceuticals Platform

New technology has the potential to make a meaningful improvement in the lives of patients.

Author Image

By: Charlie Sternberg

Associate Editor

Molecular Targeting Technologies Inc. (MTTI) and Evergreen Theragnostics Inc., have entered an agreement in which Evergreen will manufacture MTTI’s EvaThera platform of radiopharmaceuticals.   The EvaThera platform is a new generation of Evans blue-based molecules with strong affinity for albumin, which extends the blood half-life of the radiopharmaceutical, potentially leading to improved outcomes. MTTI’s leading pipeline candidates are both Lu-177 based radiotherapeutics: EBTATE, t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters